In December, global pharmaceutical company Allergan celebrated the beginning of the 30th anniversary celebration for Botox with the ringing of the New York Stock Exchange opening bell.
During the past 30 years, more than 100 million vials of Botox and Botox Cosmetic have been manufactured worldwide for various therapeutic and aesthetic uses. With two additional US Food and Drug Administration (FDA) approvals in 2019 for therapeutic indications of paediatric upper limb spasticity and lower limb spasticity, excluding spasticity caused by cerebral palsy, Botox and Botox Cosmetic now hold 14 therapeutic and aesthetic indications combined, Allergan confirms.
“This incredible milestone underscores our constant focus on innovation and motivates us to further build on our 30 years’ of research and development efforts for Botox,” said Dr Mitchell Brin, senior vice president global drug development, chief scientific officer of Botox and neurotoxins at Allergan. “For three decades, our team has been dedicated to manufacturing and delivering Botox from an unparalleled state-of-the-art facility, abiding to the strictest quality and safety standards. As we now look forward to the next 30 years and beyond, we maintain our commitment to serve patients worldwide across a wide spectrum of diseases and clinical needs,” he added.
